Bluefish completes directed new share issue – provides SEK 19.5 million

The Board of Directors in Bluefish Pharmaceuticals AB (Bluefish) has decided to complete a directed new share issue to Whochford Holding (Whochford) equivalent to SEK 19.5 million. The decision is conditioned by the general meeting’s subsequent approval. After the new share issue, Whochford will hold 7.1% of the capital and votes in Bluefish.

”Whochford is an investment company in South Asia that is well established in the Indian industry and contributes with an important network for our growing business”, says Karl Karlsson, CEO and founder of Bluefish.

Through the share issue, the number of shares in Bluefish is increased by 3 250 000 and the share capital is increased by SEK 650 000. After the share issue, the company's share capital totals SEK 9 122 944 and the number of shares totals 45 614 720. The subscription price is SEK 6 for each new share.

An extraordinary general meeting for approval of the Boards’ decision to issue new shares will take place on 19 January 2012 at 10.30 in Bluefish offices at Torsgatan 11.

For more information contact,

Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 20
Email: karl.karlsson@bluefishpharma.com

Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 21
Email: susanna.urdmark@bluefishpharma.com

About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in 19 European markets and has a technology center in Bangalore, India. The product portfolio consists of a total of 68 products and is growing.

www.bluefishpharma.com